UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~FORM 8-K

~~Current~~CURRENT ~~Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934~~REPORT

~~Date~~Pursuant ofto ~~Report~~Section 13 or 15(~~Date~~d) of ~~earliest~~the ~~event~~Securities ~~reported)~~Exchange ~~July~~Act ~~20,~~of ~~2010~~1934

~~NURX~~Date ~~PHARMACEUTICALS,~~of Report ~~INC.~~ (~~Exact~~Date ~~name~~ of ~~registrant~~earliest asevent ~~specified~~reported): August in8, ~~its charter)~~2010

Nevada		0-26694		87-0681500
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

NURX PHARMACEUTICALS, INC.

18 Technology, Suite 130, Irvine CA		92618
(Address of principal executive offices)		(Zip Code)

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (949) 336-7111 N/A (Former name or former address, if changed since last report)

Nevada	0-26694	87-0681500
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Aubade Creative

501 Santa Monica Boulevard, Suite 600

Santa Monica, CA 90401

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (310) 526-3227

Not applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 1.02. Termination~~¨ ofSoliciting amaterial ~~Material~~pursuant ~~Definitive Agreement~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

On¨ January 29, 2010, NuRx Pharmaceuticals, Inc. (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with QuantRx Biomedical Corporation, a Nevada corporation (“QuantRx”), and NP Acquisition Corporation, a Nevada corporation and a whollyPre-~~owned~~commencement ~~subsidiary~~communications ~~of QuantRx (“Merger Sub”),~~ pursuant to ~~which Merger~~Rule ~~Sub was to be merged with and into the Company, with the Company continuing as the surviving corporation and a wholly~~14d-~~owned subsidiary of QuantRx. On July 20, 2010, QuantRx terminated the Merger Agreement pursuant to Section 7.02~~2(b) ~~thereof,~~under ~~which provided that either party could terminate~~ the ~~Merger~~Exchange ~~Agreement~~Act if(17 ~~the~~CFR ~~merger had not been consummated on or prior to June 30, 2010~~240.14d-2(b))

~~The~~¨ ~~material~~Pre-commencement ~~terms~~communications ~~and~~pursuant ~~conditions~~to ~~of the~~Rule ~~Merger Agreement were previously disclosed in the Company’s Current Report on Form 8~~13e-K4(c) ~~filed~~under ~~with~~ the ~~Securities and~~ Exchange ~~Commission~~Act on(17 ~~January~~CFR ~~29, 2010, and those descriptions are incorporated herein by this reference~~240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 8, 2010, the Board of Directors of NuRx Pharmaceuticals, Inc. (the “Company”) approved a deferred compensation arrangement with respect to employment agreements of Dr. Harin Padma-Nathan, Chief Executive Officer, and Steven Gershick, Chief Financial Officer of the Company.

On May 29, 2010, in order to help the Company conserve cash for operations, Dr. Padma-Nathan began reducing the rate at which the Company paid his base salary from $325,000 to $243,750, which represents a reduction of 25%. Thereafter, on July 23, 2010, Dr. Padma-Nathan, further reduced the rate at which the Company paid his base salary to $0. Throughout this time, Dr. Padma-Nathan devoted and continues to devote 100% of his time to activities of the Company.

On May 29, 2010, in order to help the Company conserve cash for operations, Mr. Gershick reduced the rate at which the Company paid his base salary by 50%, from a rate of $252,000 per annum to $126,000 per annum, at which time Mr. Gershick reduced his full time commitment to a 50% part-time commitment commensurate with reduction in his rate of pay. Thereafter, on August 7, 2010, Mr. Gershick further reduced the rate at which the Company paid his base salary to $37,800, which represented an 85% reduction from his original base salary of $252,000. Mr. Gershick has agreed to continue to devote 1/3 of his available time to activities of the Company.

In recognition and consideration of the unpaid compensation and continuing time commitments set forth above, at its August 8, 2010 meeting the Company’s Board adopted the following deferred compensation arrangement:

The unpaid compensation to Dr. Padma-Nathan and Mr. Gershick from and after May 29, 2010, computed as the difference between (i) each executive’s base salary multiplied by the time commitment, and (ii) base salary actually paid to the executive, shall be considered “deferred compensation.” The full amount of such deferred compensation shall be paid to the executives immediately upon receipt of appropriate outside financing by the Company.

2)	The Company shall continue to provide health insurance coverage to the executives at current levels.

In connection with such deferred compensation arrangement, the Company issued to Dr. Padma-Nathan and Mr. Gershick new, fully vested options to purchase, respectively, 500,000 and 50,000 shares of the Company’s common stock at an exercise price of $0.11 per share, which was the then current fair market value of the Company’s common stock on the date of grant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NURX PHARAMCEUTICALS, INC.
	NURX PHARMACEUTICALS, INC.
July 22, 2010
Dated: August 12, 2010	By:	/s/ Steven Gershick
	By:	/s/ Steven Gershick
		Name: Steven Gershick
		Steven Gershick
		Title: Chief Financial Officer
		Chief Financial Officer

Filing Compare · NURX PHARMACEUTICALS, INC.